Original Publication Date: 1 May, 2014
Publication / Source: Breast Cancer Management
Authors: Zsuzsanna Kahán, Joanne Mortimer & Victoria L Webber
San Antonio Breast Cancer Symposium 2013, Henry B Gonzalez Convention Center, San Antonio, TX, USA, 10–14 December 2013
The San Antonio Breast Cancer Symposium 2013 was a 5-day program with 7500 attendees from over 90 countries. Once again, the symposium provided a number of practice-changing and practice-reinforcing presentations. This conference scene reports on the most important presentations, with commentary from three leading breast cancer specialists.
The oncology scene
The trial of adjuvant paclitaxel and trastuzumab for node-negative disease, HER2+ disease presented by Dr Tolaney (Dana–Farber Cancer Center, MA, USA) at the 36th San Antonio Breast Cancer Symposium (SABCS) has the potential to change clinical practice. The clinical trials supporting the approval of adjuvant trastuzumab excluded women with node-negative disease whose primary tumors were ≤1 cm .